This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00685/identifier/national-drug-code-directory/
n21http://linked.opendata.cz/resource/mesh/concept/
n14http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/drugbank/mixture/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00685/identifier/chemspider/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://www.drugs.com/mtm/
n28http://www.rxlist.com/cgi/generic/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00685/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00685/identifier/wikipedia/
n8http://linked.opendata.cz/resource/drugbank/patent/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/ontology/mesh/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00685/identifier/bindingdb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00685/identifier/kegg-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00685/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00685/identifier/pubchem-substance/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00685/identifier/drugbank/
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00685
rdf:type
n3:Drug
n3:description
Trovafloxacin (sold as Trovan by Pfizer) is a broad spectrum antibiotic that inhibits the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was withdrawn from the market due to the risk of hepatotoxicity. It had better gram-positive bacterial coverage and less gram-negative coverage than the previous fluoroquinolones. [Wikipedia]
n3:group
withdrawn approved
n3:halfLife
Following oral administration, half-life ranged from 9.1 hours to 12.2 hours over the dosage range of 100 to 200 mg tablets. Following intravenous infusion, half-life ranged from 9.4 to 12.7 hours over a dosage range of 100 to 300 mg.
n3:indication
For treatment of infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by <i>Neisseria gonorrhoeae</i> as well as non gonoccocal urethritis and cervicitis due to <i>Chlamydia trachomatis</i>.
n3:manufacturer
n14:271B44F7-363D-11E5-9242-09173F13E4C5 n14:271B44F8-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00685 n25:DB00685
dcterms:title
Trovafloxacin
adms:identifier
n12:PA164749184 n13:Trovafloxacin n17:62959 n18:46508751 n19:0049-3890-28 n22:50146361 n23:C07664 n24:56670 n26:DB00685
n3:mechanismOfAction
Trovafloxacin is a fluoronaphthyridone related to the fluoroquinolones with in vitro activity against a wide range of gram-negative and gram-positive aerobic and anaerobic microorganisms. The bactericidal action of trovafloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription, and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
n3:packager
n14:271B44F6-363D-11E5-9242-09173F13E4C5
n3:patent
n8:6187341 n8:2023217 n8:5164402
n3:routeOfElimination
Approximately 50% of an oral dose is excreted unchanged (43% in the feces and 6% in the urine).
n3:toxicity
Symptoms of overdose include convulsions, decreased activity, diarrhea, sleepiness, tremors, and/or vomiting.
n3:mixture
n27:271B44F5-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
The mean plasma protein bound fraction is approximately 76%, and is concentration-independent.
n3:salt
n20:hasConcept
n21:M0214301
foaf:page
n16:trovafloxacin.html n28:trovazit.htm
n3:IUPAC-Name
n4:271B44FD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4503-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4502-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B44FF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4500-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4501-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4513-363D-11E5-9242-09173F13E4C5 n4:271B44FB-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B44F9-363D-11E5-9242-09173F13E4C5 n4:271B4514-363D-11E5-9242-09173F13E4C5 n4:271B44FC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B44FA-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:J01MA13
n3:H-Bond-Acceptor-Count
n4:271B4509-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B450A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4504-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4505-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4507-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4506-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4508-363D-11E5-9242-09173F13E4C5
n3:absorption
Well-absorbed from the gastrointestinal tract after oral administration and does not depend on concomitant food intake. The absolute bioavailability is approximately 88%.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
147059-72-1
n3:category
n3:Bioavailability
n4:271B450F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4511-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4512-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B450E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B450D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4510-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B44FE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B450B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B450C-363D-11E5-9242-09173F13E4C5